Zoledronic acid: A mischievous suspect for liver injury

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 47-year-old male diagnosed as adenocarcinoma of the lung and received 8 cycles of chemotherapy comprising intravenous administration of cisplatin 125 mg, pemetrexed 850 mg along with zoledronic acid 4 mg. After the completion of the 8th cycle, the liver enzymes were found to be markedly elevated, evincing zoledronic acid as the cause for hepatotoxicity. The case details were taken from the patient’s medical record along with the biochemical test reports and radiographic images. The causal association was confirmed using Naranjo’s algorithm and Roussel Uclaf Causality Assessment Method (RUCAM). After the uneventful chemotherapy, patient’s liver function tests (LFT) were abnormal. There was an elevation in the aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and direct bilirubin. The causal relationship was established using Naranjo’s algorithm (score-6) and RUCAM (score-5), displayed a “probable” and “possible” association. Hartwig’s severity scale and Thornton’s preventability scale displayed the adverse drug reaction to being moderately severe and not preventable, respectively. The zoledronic acid was stopped and never readministered. The LFTs assumed normal after a span of 2 months. The mechanism underlying hepatotoxicity due to zoledronic acid remains elusive. Zoledronic acid can induce acute phase response mediated by active production of interleukin-6, tumor necrosis factor alpha, and pro-inflammatory cytokines from the T-cells and macrophages. Vigilant monitoring along with timely assessment and management can prevent the occurrence of irreversible liver damage. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid.

Original languageEnglish
Pages (from-to)3-6
Number of pages4
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume9
DOIs
Publication statusPublished - 01-10-2016

Fingerprint

zoledronic acid
Liver
Wounds and Injuries
Causality
Pemetrexed
Drug Therapy
Acute-Phase Reaction
Liver Function Tests
Incidence
Aspartate Aminotransferases
Drug-Related Side Effects and Adverse Reactions
Alanine Transaminase
Bilirubin
Pharmaceutical Preparations
Intravenous Administration
Cisplatin
Medical Records
Alkaline Phosphatase
Interleukin-6

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{b180c45b3fa044aea765d52eb7ddeeb6,
title = "Zoledronic acid: A mischievous suspect for liver injury",
abstract = "A 47-year-old male diagnosed as adenocarcinoma of the lung and received 8 cycles of chemotherapy comprising intravenous administration of cisplatin 125 mg, pemetrexed 850 mg along with zoledronic acid 4 mg. After the completion of the 8th cycle, the liver enzymes were found to be markedly elevated, evincing zoledronic acid as the cause for hepatotoxicity. The case details were taken from the patient’s medical record along with the biochemical test reports and radiographic images. The causal association was confirmed using Naranjo’s algorithm and Roussel Uclaf Causality Assessment Method (RUCAM). After the uneventful chemotherapy, patient’s liver function tests (LFT) were abnormal. There was an elevation in the aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and direct bilirubin. The causal relationship was established using Naranjo’s algorithm (score-6) and RUCAM (score-5), displayed a “probable” and “possible” association. Hartwig’s severity scale and Thornton’s preventability scale displayed the adverse drug reaction to being moderately severe and not preventable, respectively. The zoledronic acid was stopped and never readministered. The LFTs assumed normal after a span of 2 months. The mechanism underlying hepatotoxicity due to zoledronic acid remains elusive. Zoledronic acid can induce acute phase response mediated by active production of interleukin-6, tumor necrosis factor alpha, and pro-inflammatory cytokines from the T-cells and macrophages. Vigilant monitoring along with timely assessment and management can prevent the occurrence of irreversible liver damage. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid.",
author = "Rupam Gill and O. Balaji and {Meena Kumari}, K. and {Amberkar Mohan}, {Babu V.} and Udupa, {Karthik S.}",
year = "2016",
month = "10",
day = "1",
doi = "10.22159/ajpcr.2016.v9s2.13412",
language = "English",
volume = "9",
pages = "3--6",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",

}

TY - JOUR

T1 - Zoledronic acid

T2 - A mischievous suspect for liver injury

AU - Gill, Rupam

AU - Balaji, O.

AU - Meena Kumari, K.

AU - Amberkar Mohan, Babu V.

AU - Udupa, Karthik S.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - A 47-year-old male diagnosed as adenocarcinoma of the lung and received 8 cycles of chemotherapy comprising intravenous administration of cisplatin 125 mg, pemetrexed 850 mg along with zoledronic acid 4 mg. After the completion of the 8th cycle, the liver enzymes were found to be markedly elevated, evincing zoledronic acid as the cause for hepatotoxicity. The case details were taken from the patient’s medical record along with the biochemical test reports and radiographic images. The causal association was confirmed using Naranjo’s algorithm and Roussel Uclaf Causality Assessment Method (RUCAM). After the uneventful chemotherapy, patient’s liver function tests (LFT) were abnormal. There was an elevation in the aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and direct bilirubin. The causal relationship was established using Naranjo’s algorithm (score-6) and RUCAM (score-5), displayed a “probable” and “possible” association. Hartwig’s severity scale and Thornton’s preventability scale displayed the adverse drug reaction to being moderately severe and not preventable, respectively. The zoledronic acid was stopped and never readministered. The LFTs assumed normal after a span of 2 months. The mechanism underlying hepatotoxicity due to zoledronic acid remains elusive. Zoledronic acid can induce acute phase response mediated by active production of interleukin-6, tumor necrosis factor alpha, and pro-inflammatory cytokines from the T-cells and macrophages. Vigilant monitoring along with timely assessment and management can prevent the occurrence of irreversible liver damage. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid.

AB - A 47-year-old male diagnosed as adenocarcinoma of the lung and received 8 cycles of chemotherapy comprising intravenous administration of cisplatin 125 mg, pemetrexed 850 mg along with zoledronic acid 4 mg. After the completion of the 8th cycle, the liver enzymes were found to be markedly elevated, evincing zoledronic acid as the cause for hepatotoxicity. The case details were taken from the patient’s medical record along with the biochemical test reports and radiographic images. The causal association was confirmed using Naranjo’s algorithm and Roussel Uclaf Causality Assessment Method (RUCAM). After the uneventful chemotherapy, patient’s liver function tests (LFT) were abnormal. There was an elevation in the aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and direct bilirubin. The causal relationship was established using Naranjo’s algorithm (score-6) and RUCAM (score-5), displayed a “probable” and “possible” association. Hartwig’s severity scale and Thornton’s preventability scale displayed the adverse drug reaction to being moderately severe and not preventable, respectively. The zoledronic acid was stopped and never readministered. The LFTs assumed normal after a span of 2 months. The mechanism underlying hepatotoxicity due to zoledronic acid remains elusive. Zoledronic acid can induce acute phase response mediated by active production of interleukin-6, tumor necrosis factor alpha, and pro-inflammatory cytokines from the T-cells and macrophages. Vigilant monitoring along with timely assessment and management can prevent the occurrence of irreversible liver damage. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid. Henceforth, we would like to report the rare incidence of drug induced hepatic damage due to zoledronic acid.

UR - http://www.scopus.com/inward/record.url?scp=84991406549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991406549&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2016.v9s2.13412

DO - 10.22159/ajpcr.2016.v9s2.13412

M3 - Article

AN - SCOPUS:84991406549

VL - 9

SP - 3

EP - 6

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

ER -